Royalty Pharma (NASDAQ:RPRX) is a biopharmaceutical royalty company headquartered in New York City. Founded in 1996 by Pablo Legorreta, the firm acquires royalty and revenue interests in biopharmaceutical products at various stages of development. By purchasing future royalty streams, Royalty Pharma provides biotechnology and pharmaceutical companies with non-dilutive capital to advance drug discovery, development, and commercialization.
The company’s core business involves structuring and financing transactions that grant it rights to a portion of future sales from therapies ranging from oncology and immunology to rare diseases and neuroscience. Royalty Pharma evaluates potential acquisitions based on clinical data, commercial forecasts, and regulatory milestones, enabling it to build a diversified portfolio that balances marketed products with earlier‐stage assets.
Over the years, Royalty Pharma has assembled a broad portfolio that includes interests in blockbuster and specialty therapies developed by leading pharmaceutical companies. Its transactions often involve well-known medicines alongside emerging therapeutics, reflecting a strategy designed to generate stable, long‐term cash flows while supporting innovation across global markets.
Under the leadership of founder and Chief Executive Officer Pablo Legorreta, Royalty Pharma operates in more than 20 countries across North America, Europe, and Asia. The company collaborates with research institutions, biotechnology firms, and major pharmaceutical companies, acting as a financial partner that enables life sciences organizations to accelerate the delivery of new treatments to patients worldwide.
